AMiAware, by unanimous decision, took First Place at the Boston Scientific Challenge. VantageLinks CEO, Leah Amir heads up the AMiAware development team. Our patented technology is guiding the path to timely meaningful clinical decisions. The prognostic markers have over 12 years of study to verify their role in plaque rupture. Through collaboration with the Mayo Clinic and Boston Scientific the FDA clearance process is underway. Enjoy our segment of Boston Scientific Challenge presentation, edited for time.
